Keywords: kosan, starts, trials, kos-1022, kos, cancer, therapy

Kosan starts trials of KOS-1022 and KOS 953 in cancer therapy

Article | 30 January 2006

Print This

US drugmaker Kosan Biosciences says it has initiated a Phase I multicenter trial of KOS-1022, its second-generation heat shock protein 90 ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in